Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ARX-788 |
Synonyms | |
Therapy Description |
ARX-788 is an antibody-drug conjugate (ADC) comprising a dolastatin analog and an antibody specific to ERBB2 (HER2), which may result in cell death and tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639, PMID: 30841523, PMID: 32669315). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ARX-788 | ARX788|ARX 788 | HER2 (ERBB2) Antibody 76 HER2 (ERBB2) Antibody-Drug Conjugate 31 | ARX-788 is an antibody-drug conjugate (ADC) comprising a dolastatin analog and an antibody specific to ERBB2 (HER2), which may result in cell death and tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639, PMID: 30841523, PMID: 32669315). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05041972 | Phase II | ARX-788 | ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) | Withdrawn | USA | 0 |
NCT03255070 | Phase I | ARX-788 | A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) | Completed | USA | AUS | 0 |
NCT06224673 | Phase II | ARX-788 | ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer | Not yet recruiting | USA | 0 |
NCT04829604 | Phase II | ARX-788 | ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) | Recruiting | USA | FRA | AUS | 1 |